Diligence memo · auto-generated · as of July 2, 2026

Olive Pharmacy, LLC

Olive Pharmacy, LLC looks under-valued against its niche peers and is dormant on financing cadence.

DeprioritizeFinancing has gone silent well past the sector's normal cadence — treat as inactive until outside confirmation of a live operation.

Businessfiled

Olive Pharmacy, LLC operates in Biotech / Pharma, based in DALLAS.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

Olive Pharmacy, LLC has raised $100K in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Pre-Seed (a round under $1.0M).

Largest single filing: $100K on 2017-11-09.

Most recent recorded round closed around 2017-11-09.

Valuation (modeled)modeled

Provath models Olive Pharmacy, LLC at approximately $5.1M (range $55K–$58M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Under-valued. Modeled value is 0.29× the median modeled value of Pre-Seed Biotech / Pharma companies in 2016–2018 (12 peers) — value vs value, same stage and era. Issuer reports $5M–$25M revenue while modeled below niche peers.

Financing rhythm & timingmixed

Last raise 8.6 yr ago; this sector typically re-raises about every 15 months.

Only one round on record and long silent — often defunct, acquired, or gone quiet.

Comparablesmixed

Capital scale ranks ahead of 7% of Biotech / Pharma peers (227 compared).

Modeled value ranks above 27% of those peers.

Closest niche peers: Orbis Biosciences, Inc, Nexion Biosciences Inc, Synereca Pharmaceuticals, Inc., Novome Biotechnologies, Inc., Me Biosciences, Inc..

Peoplefiled

1 named person on file across officers, directors and signatories.

Risks & flagsmixed

Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.